Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
NCT ID: NCT04186026
Last Updated: 2023-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
35 participants
INTERVENTIONAL
2019-10-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
NCT02598791
The Interaction Between Appetite Hormones
NCT02094183
GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake
NCT03526289
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
NCT01079624
Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.
NCT01232244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Studies in rodents have shown that a GLP-1 receptor agonist and long acting neurotensin inhibit food intake.
This study investigates whether the synergistic anorexic effects of neurotensin and GLP-1 agonism suggested by animal studies can be translated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saline+Saline
Saline + saline
Double saline infusion followed by an ad libitum meal
Neurotensin+Saline
Neurotensin + saline
Neurotensin + saline infusion followed by an ad libitum meal
GLP-1+Saline
GLP-1 + saline
GLP-1 + saline infusion followed by an ad libitum meal
Neurotensin + GLP-1
GLP-1 + Neurotensin
GLP-1 + Neurotensin infusion followed by an ad libitum meal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saline + saline
Double saline infusion followed by an ad libitum meal
Neurotensin + saline
Neurotensin + saline infusion followed by an ad libitum meal
GLP-1 + saline
GLP-1 + saline infusion followed by an ad libitum meal
GLP-1 + Neurotensin
GLP-1 + Neurotensin infusion followed by an ad libitum meal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Above 18 years of age
* Normal hemoglobin concentration
* 28\<BMI\<40 kg/m2
Exclusion Criteria
* Truncal vagotomy
* Resection of intestine (apart from appendectomy)
* Tobaccos use
* Nephropathy (serum-creatinin\>130 micromolar or/and albuminuria)
* Liver disease (Alanine transaminase or/and aspartate transaminase\>2 times normal range.)
* Treatment with medication that cannot be paused in 12 hours
* Allergy towards latex or plastic
* Bleeding disorder
18 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Copenhagen University Hospital, Hvidovre
OTHER
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Birgitte Holst
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Copenhagen, Department of Biomedical Scienses
Copenhagen, , Denmark
Copenhagen University Hospital Hvidovre
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
514-0386/19-3000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.